Lifecore Biomedical Q4 Adjusted EPS $(0.11) Beats $(0.37) Estimate, Sales $31.55M Beat $29.02M Estimate
Portfolio Pulse from Benzinga Newsdesk
Lifecore Biomedical (NASDAQ:LFCR) reported Q4 losses of $(0.11) per share, beating the analyst consensus estimate of $(0.37) by 70.27%. This is a 1000% decrease over losses from the same period last year. The company also reported quarterly sales of $31.55 million, beating the analyst consensus estimate of $29.02 million by 8.70%. However, this is a 33.76% decrease over sales from the same period last year.
August 31, 2023 | 11:42 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Lifecore Biomedical reported better-than-expected Q4 results, but both earnings and sales have significantly decreased compared to the same period last year.
While Lifecore Biomedical's Q4 results beat analyst estimates, the significant year-over-year decreases in both earnings and sales could potentially offset any positive impact from the earnings beat. This creates uncertainty about the short-term price direction.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100